House Energy and Commerce Committee leaders yesterday sent letters to nine contract pharmacies that participate in the 340B drug savings program requesting information about their participation in the program. The letters sought information on contracting practices; the distance between covered entities and contract pharmacies; to what degree contract pharmacies prevent duplicate discounts or diversion in the program; and whether contract pharmacies ensure low-income uninsured patients do not face high drug costs despite the program’s discount. The letters follow a June Government Accountability Office report recommending that the Health Resources and Services Administration take additional steps to ensure contract pharmacies comply with 340B requirements.
 

Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The White House May 18 announced an expansion of TrumpRx.gov, which now features more than 600 generic drugs. The direct-to-consumer platform serves as a hub…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
The Department of Health and Human Services yesterday announced an action plan on psychiatric prescribing, including efforts to initiate …